BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
12/18/2024 7:36:01 AM | Browse: 402 | Download: 875
Publication Name World Journal of Gastroenterology
Manuscript ID 100827
Country China
ISSN 1007-9327 (print) and 2219-2840 (online)
Open Access This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Copyright © The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Medicine, Research & Experimental
Manuscript Type Letter to the Editor
Article Title Exploring gut microbiota as a novel therapeutic target in Crohn’s disease: Insights and emerging strategies  
Manuscript Source Invited Manuscript
All Author List Tong Qiao and Xian-Hui Wen
ORCID
Author(s) ORCID Number
Xian-Hui Wen http://orcid.org/0009-0002-0905-8738
Funding Agency and Grant Number
Corresponding Author Xian-Hui Wen, PhD, College of Life Science and Technology, Jinan University, No. 601 Huangpu Avenue West, Tianhe District, Guangzhou 510632, Guangdong Province, China. 17818521036@163.com
Key Words Crohn’s disease; Gut microbiome; Dysbiosis; Creeping fat; Fecal microbiota transplantation
Core Tip Crohn’s disease (CD) represents a complex and challenging medical condition, characterized by the intricate interplay between genetic predisposition, gut microbiota dysbiosis, and immune dysregulation. We have discussed the key effects of gut microbiota on CD, as well as how they affect creeping fat. Furthermore, we highlight the urgent need to address gut microbiota imbalances, particularly focusing on pathogenic species and their mechanisms, as a critical therapeutic target. Our findings underscore the importance of a personalized approach to CD management, emphasizing the need for continued research and innovation to address this complex disease.  
Publish Date 2024-12-18 07:36
Citation

Qiao T, Wen XH. Exploring gut microbiota as a novel therapeutic target in Crohn’s disease: Insights and emerging strategies. World J Gastroenterol 2025; 31(2): 100827

URL https://www.wjgnet.com/1007-9327/full/v31/i2/100827.htm
DOI https://dx.doi.org/10.3748/wjg.v31.i2.100827
Full Article (PDF) WJG-31-100827-with-cover.pdf